Prognostic marker analysis in pediatric intracranial ependymomas

Area of Science:

• Pediatric Neuro-oncology
• Cancer Biomarkers
• Histopathology

Background:

• Histologic grading of intracranial ependymomas using H&E staining lacks reliable survival prediction in pediatric patients due to subjectivity.
• Immunohistochemistry offers potential for objective biomarker discovery in pediatric brain tumors.

Purpose of the Study:

• To investigate if immunohistochemical markers (MIB-1, Tenascin C, CD34, VEGF, CA IX) can serve as objective predictors of progression-free survival (PFS) and overall survival (OS) in pediatric intracranial ependymomas.
• To compare the predictive value of these markers against traditional H&E-based grading.

Main Methods:

• Analysis of intracranial ependymomas from pediatric patients (≤22 years).
• Histologic grading (WHO system), H&E review for vascular proliferation, and immunohistochemistry for MIB-1, Tenascin C, CD34, VEGF, and CA IX.
• Correlation of marker status with PFS and OS using survival analysis.

Main Results:

• Traditional WHO grade did not correlate with PFS or OS.
• Perinecrotic Carbonic Anhydrase IX (CA IX) localization correlated significantly with both PFS and OS.
• MIB-1 labeling index (LI) also showed significant correlation with OS and PFS.
• CA IX staining was associated with vascular proliferation but not VEGF expression.

Conclusions:

• Immunodetection of CA IX and MIB-1 expression are significant predictive biomarkers for survival in pediatric posterior fossa ependymomas.
• These objective markers supplement traditional H&E grading, improving prognostic accuracy for pediatric intracranial ependymomas.